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Abstract
We characterized bone marrow stromal cells (BMSC) from patients with pre-fibrotic myeloproliferative neoplasms
(MPN). MPN-BMSC showed decreased capacity to stimulate the proliferation of colony-forming units of normal
hematopoietic stem and progenitor cells and displayed increased matrix remodelling (in particular fibronectin
deposition) compared to control BMSC. This finding was confirmed in pre-fibrotic MPN bone marrow biopsies
in a tissue microarray (n= 34), which stained positive for fibronectin in the absence of reticulin as a standard
myelofibrosis marker. Fibronectin expression correlated significantly with reduced haemoglobin levels in MPN-patients
(p=0.007; R2=0.42). Our data show significant cell-intrinsic alterations in MPN-MSC and suggest that Fibronectin
expression might be applicable as a biomarker for the identification of early myelofibrotic transformation in
reticulin-negative MPN.
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Findings
It remains elusive if human bone-marrow mesenchymal
stromal cells (BMSC) display an intrinsic role in the
development of myelofibrosis independent of the malig-
nant clone. We applied a three-dimensional collagen
culture-system as an in vitro-screening for the functional
characterization of BMSC isolated from MPN-patients
[1,2]. The assay was designed to be applicable for poten-
tial diagnostic and prognostic utility in the investigation
of progressive myelofibrosis. The main question of the
study was if MPN-MSCs functionally differ from MSCs
isolated from healthy donors in (i) their matrix remodel-
ling and (ii) hematopoiesis-supporting capacity. MSC
were isolated from patients with ET (n =4), PV (n =5),
CML (n= 5), all without or only mild myelofibrosis, one
patient with post essential thrombocythemia myelofibrosis
(ET-MF, n=1) as well as from control patients (non-
MPN, n=6), (Figure 1a). MSC were isolated from bone
marrows by plastic adherence. No significant differences
were detected in (1) the number of proliferating mesen-
chymal precursors (CFU-F), (2) MSC morphology, (3)
osteoblastic and adipogenic differentiation or (4) the sur-
face marker pattern of MPN- and control-MSC. In line
with previous reports, (RT)-PCR examination of cultured
BMSC neither detected the JAK2-V617F mutation nor the
BCR-ABL fusion transcript, despite the fact that 3/5 of ET
cases and 5/5 of PV were positive for the JAK2-V617F
mutation and all CML cases (5/5) were positive for BCR-
ABL translocation in peripheral blood cells (Figure 1b).
To characterize the hematopoiesis-supporting capacity
of MSC, secreted cytokines and their biological activity
were tested. ET-MSC secreted significantly lower levels
of G-CSF and IL-7 compared to controls, indicating a
defect in the hematopoiesis-supporting capacity (Figure 1c).
We therefore evaluated the biological activity of secreted
cytokines in myeloid colony-forming unit (CFU) assays
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+-hematopoietic stem
and progenitor cells (HSPCs) [3]. Myeloid CFU-activity
significantly decreased when supernatants from PV and
CML were used (Figure 1d). These findings indicate that
MPN-BMSCs lose their capacity to produce and release
functional myeloid differentiation-supporting cytokines.
Further, we tested MPN-BMSCs for their capacity to
remodel extracellular matrix (ECM) in the absence of the
hematopoietic clone [1,2]. MSC isolated from ET induced
a significant reduction of the collagen area accompanied
by enhanced matrix stiffening (Figure 1e). We analysed if
the contraction potential involves matrix production and
scored protein and gene expression of matrix components.
A significant up-regulation of the ECM protein fibronec-
tin was detected in ET-MSC by immunohistochemistry
(Figure 1f). We next asked if ECM remodelling and the
significant differential fibronectin expression can be attrib-
uted to MSC in correlating bone marrow biopsies of MSC
donors. We applied CD271 for the identification of MSC
in bone marrow biopsies as this marker most faithfully
identifies the heterogenous stromal cell (MSC) population
in the human bone marrow up-to-date [4]. Our first
finding was that the distribution of CD271
+ MSC sig-
nificantly differed in MPN biopsies compared to the
control bone marrow (Figure 2a). In controls, CD271
was mainly expressed in the endosteal and vascular niche
[5]. In MPN entities however, CD271
+ cells were mobi-
lized from these niches and identified in association to
dysplastic megakaryocytes (Figure 2a). Our second finding
was that fibronectin is expressed in association to CD271
in the hematopoietic niches of the bone marrow in control
donors. In striking contrast, fibronectin was diffusely
up-regulated in association to expanded stromal cells
and identified unbound to the ECM in MPN (Figure 2b)
as well as in association to megakaryocytes (Figure 2f).
To validate these findings, we systematically analyzed
CD271 and fibronectin in tissue microarrays including ET
(n=13), PV (n =11), CML (n=14), PMF (n =11) and non-
Figure 1 In vitro screening approach of hematopoiesis-supporting and matrix remodelling capacities of MPN-MSC. (a) Clinical and
laboratory characteristics of MPN-MSC donors and control cases. Reticulin fibrosis was evaluated according to the European consensus. y, years;
Hb, haemoglobin levels; WBC, white blood cell count; PLT, platelet count; n.d. not determined. (b) BMSCs were isolated from BM of patients with
MPN or control donors by plastic adherence. RT-PCR analysis detecting the BCR-ABL gene (left) or JAK2-V617F mutation (right) in cultured BMSC
(passage 2). (c) Protein levels of G-CSF and IL-7 in BMSC supernatants (passage 2), (mean±SD, n=5 each, *p< 0.05). (d) CFU activity of 500 sorted
human CB CD34
+ cells in the presence of supernatants from BMSC (mean±SD, n=5 for control, PCV and CML; n=4 for ET, *p<0.05). (e) Contraction
of the original collagen gel area (upper panel) in collagen gels after 28 days (mean±SD, n=5 each, **p<0.05). (f) Messenger RNA levels of fibronectin
in BMSC in 3D collagen after 28 days of culture. Expression levels are normalized against GAPDH. (mean±SD, n=5 each, non-signficant). Quantification
of fibronectin expression in collagen gels represented in panel 2–6 by 2 independent researchers (according to grading scale 0–6 below panels).
(mean±SD, n=5 each, *p<0.05).
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were evaluated applying a grading scheme similar to the
established guidelines for grading myelofibrosis – 0=no
fibrosis and 3=severe myelofibrosis [6]. Although the ma-
jority of MPN cases were classified as myelofibrosis grade
0–1 in reticulin-staining, myelofibrotic transformation was
graded as≥1 by Fibronectin-staining in 69% of ET (vs.
7.7% Reticulin-representing one post ET-MF patient), 63%
of PV (vs. 0% Reticulin) and 100% CML (vs. 0% Reticulin)
cases and by CD271 staining in 54% of ET, 51% PV and
64% CML cases (Figure 2d). In line with the observation of
a pre-fibrotic marrow, fibronectin and CD271 expression
grade correlated significantly with decreased haemoglobin
levels in reticulin-negative biopsies (Figure 2e).
In conclusion, our data reveal an intrinsic defect of MSC
in pre-fibrotic MPN resulting in decreased hematopoiesis-
supporting capacities and increased ECM remodelling. Our
data suggest that fibronectin up-regulation/distribution
detects early myelofibrotic changes in the BM of MPN
patients and implies clinical and prognostic application in
different myeloproliferative (Ph
− and Ph
+) neoplasms.
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Figure 2 In vivo validation of the fibronectin-secretory phenotype of MPN-MSC. (a) Representative Fibronectin and CD271 expression in
correlating bone marrow biopsies of MPN-MSC donors. (b) Co-localization of fibronectin and CD271 expression by confocal microscopy. CD271
(green, Alexa Fluor 488) and fibronectin (red, Alexa Fluor 555) were analysed separately (panel 1 and 2) and merged (panel 3) with the nuclear
counterstain TO-PRO®-3 Iodide (blue, excitation at 633 nm). Cytoplasmatic extensions of CD271
+ MSC co-localize with Fibronectin, in particular in
association to megakaryocytes (Mk). (c) Clinical and laboratory characteristics of patient samples included in the tissue microarray (TMA). y, years; Hb,
haemoglobin levels. (d) Fibronectin grading was adapted to Reticulin grading (Thiele et al.) in reticulin-negative MPN TMA samples. (e) Correlation of
fibronectin-grading in reticulin-negative graded TMA samples to haemoglobin levels. Box plots show minimal, quartile, median and maximal values ine a c h
group, (+)=mean value. (f) Schematic depicting the hypothesis that MSC reside in the endosteal (and vascular) niche under steady state conditions
and are activated from these niche by dysplastic megakaryocytes (Mk) and the neoplastic clone (LT-HSC). Once activated, MPN-MSC acquire a secretory
phenotype that facilitates MSC migration, matrix contraction and provides a provisional matrix for collagen (Col) fibres in more progressed fibrosis.
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